BioCentury on BioBusiness,
Analyst Picks & Changes
Analyst picks & changes
Published on
Monday, October 1, 2012
|
Company
|
Bank
|
Analyst
|
Coverage
|
Opinion
|
Wk
chg
|
9/28
cls
|
|
Peregrine
Pharmaceuticals Inc. (NASDAQ:PPHM)
|
MLV
|
George
Zavoico
|
Downgrade
|
Hold
(from buy)
|
-81%
|
$1.03
|
|
|
Roth
Capital Partners
|
Joseph
Pantginis
|
Downgrade
|
Neutral
(from buy)
|
|
|
|
Zavoico
also removed his target after Peregrine discovered "major discrepancies
between some patient sample test results and patient treatment code
assignments" in Phase IIb data for bavituximab in second-line non-small
cell lung cancer (NSCLC) (see B19). Peregrine said investors should
not rely on data reported from the trial, including an announcement in
September that bavituximab plus docetaxel significantly improved median
overall survival (OS) vs. docetaxel alone. The company is reviewing the
source and effect of the discrepancies, but said they "appear to have
been associated with the independent third party contracted to code and
distribute investigational drug product."
|
|
Pantginis
also lowered his target to $0.70 from $9 on the bavituximab news.
|
|
Questcor
Pharmaceuticals Inc. (NASDAQ:QCOR)
|
Jefferies
|
Biren
Amin
|
Price
target
|
Hold
|
-39%
|
$18.47
|
|
|
Ladenburg
Thalmann
|
Juan
Sanchez
|
Downgrade
|
Neutral
(from buy)
|
|
|
|
|
Leerink
|
Marko
Kozul
|
Downgrade
|
Market
perform (from outperform)
|
|
|
|
|
Roth
Capital Partners
|
Yale
Jen
|
Price
target
|
Buy
|
|
|
|
|
ThinkEquity
|
James
Molloy
|
Downgrade
|
Hold
(from buy)
|
|
|
185
words displayed of
919
words total.
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2013 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement and the BioCentury Terms of Use. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions at www.biocentury.com. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
|
Current Subscribers
If you are a current subscriber, log in below or in the upper right corner of this
page.
Log In
Subscription Option
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thank You
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
records.
close [ X ]